![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Non-Sponsored Content
Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced renal cell carcinoma
By: scienterrific | Last updated: 16 April 2018 | In: Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology, Immunotherapy
Article Keywords
Opdivo, Yervoy, RCC, nivolumab, FDA, ipilimumab, BMS, Bristol-Myers Squibb
The FDA granted approvals to the combination nivolumab plus ipilimumab (Opdivo® plus Yervoy®, Bristol-Myers Squibb) for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. More Information.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!